Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Liabilities and Shareholders Equity (2017 - 2025)

Cue Biopharma's Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $31.6 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 29.38% year-over-year to $31.6 million; the TTM value through Sep 2025 reached $126.8 million, down 37.42%, while the annual FY2024 figure was $32.2 million, 47.68% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $31.6 million at Cue Biopharma, down from $40.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $91.3 million in Q4 2022 and bottomed at $22.3 million in Q1 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $73.2 million (2023), against an average of $65.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 46.29% in 2021 before it crashed 58.75% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $83.4 million in 2021, then increased by 9.45% to $91.3 million in 2022, then plummeted by 32.59% to $61.5 million in 2023, then tumbled by 47.68% to $32.2 million in 2024, then dropped by 1.7% to $31.6 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Liabilities and Shareholders Equity are $31.6 million (Q3 2025), $40.7 million (Q2 2025), and $22.3 million (Q1 2025).